SCHEDULE 13G/A
Statement of Beneficial Ownership
ENANTA PHARMACEUTICALS INC Filed Acc 0000908834-26-000532
Stakes reported in this filing
| Reporting person | Shares | Of the class |
|---|---|---|
| Farallon Capital Management, L.L.C. | 950,000 | 3.3% |
| Dapice Joshua J. | 950,000 | 3.3% |
| Dreyfuss, Philip D. | 950,000 | 3.3% |
| Dunn Hannah E. | 950,000 | 3.3% |
| Gehani, Varun N. | 950,000 | 3.3% |
| Giauque, Nicolas | 950,000 | 3.3% |
| Husen, Avner A. | 950,000 | 3.3% |
| Kim, David T. | 950,000 | 3.3% |
| Linn, Michael G. | 950,000 | 3.3% |
| Luo Patrick (Cheng) | 950,000 | 3.3% |
| Roberts, Jr., Thomas G. | 950,000 | 3.3% |
| Saito Edric C. | 950,000 | 3.3% |
| Short Daniel S. | 950,000 | 3.3% |
| Spokes, Andrew J. M. | 950,000 | 3.3% |
| Warren, John R. | 950,000 | 3.3% |
| Wehrly, Mark C. | 950,000 | 3.3% |
Members of a group can each report the same shares, so these rows overlap and don't add up.
Stake history · largest stake in each 13D and 13G
Loading xslSCHEDULE_13G_X02/primary_doc.xml…